Why the study?
Endomyocardial biopsy is the gold standard for diagnosing myocardial fibrosis but has clinical limitations, prompting the need for noninvasive assessment via biomarkers.
What is the role of collagen-related biomarkers in the noninvasive assessment of myocardial fibrosis?
What is the role of collagen-related biomarkers in the noninvasive assessment of myocardial fibrosis?
Collagen-related biomarkers offer a noninvasive alternative to endomyocardial biopsy for assessing myocardial fibrosis.
May aid noninvasive fibrosis assessment; leaves open prospective validation before clinical adoption.
Myocardial fibrosis is observed in various cardiovascular diseases and plays a key role in the impairment of cardiac function. Endomyocardial biopsy, as the gold standard for the diagnosis of myocardial fibrosis, has limitations in terms of clinical application. Therefore, biomarkers have been recommended for noninvasive assessment of myocardial fibrosis. This review discusses the role of biomarkers in myocardial fibrosis from the perspective of collagen.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: